Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biofrontera Inc

0.6900
-0.0215-3.02%
Volume:165.23K
Turnover:108.29K
Market Cap:6.52M
PE:-0.41
High:0.6922
Open:0.6600
Low:0.6401
Close:0.7115
Loading ...

Biofrontera Glycol-Free Skin Gel Added to FDA 'Orange Book;' Shares Rise

MT Newswires Live
·
04 Jun

Biofrontera announces inclusion of patent in FDA Orange Book

TIPRANKS
·
04 Jun

Biofrontera AG’s Q1 2025 Earnings Call Highlights

TIPRANKS
·
28 May

Biofrontera AG Faces Financial Uncertainty Amid Biofrontera Inc. Payment Issues

TIPRANKS
·
28 May

Biofrontera Says Co And Units Have Entered Into An Agreement With Biofrontera Inc About How To Settle Payment Obligations By Biofrontera Inc

Reuters
·
28 May

Biofrontera Inc. Faces Uncertainty as Financial Outlook for 2025 Remains Unclear and Dependent on Capital Raising Efforts

Reuters
·
28 May

Biofrontera Receives Nasdaq Non-Compliance Notice

TIPRANKS
·
24 May

Biofrontera Inc. Receives Nasdaq Notice for Non-Compliance with Listing Rule Due to Insufficient Stockholders' Equity

Reuters
·
24 May

Biofrontera, Inc. Earnings Call: Growth Amid Challenges

TIPRANKS
·
20 May

Biofrontera Is Maintained at Buy by Benchmark

Dow Jones
·
19 May

Biofrontera Inc. price target lowered to $2.75 from $7 at Benchmark

TIPRANKS
·
19 May

Biofrontera’s Strategic Advancements and Promising Prospects Justify Buy Rating

TIPRANKS
·
19 May

Biofrontera Inc : Benchmark Cuts Target Price to $2.75 From $7

THOMSON REUTERS
·
19 May

Biofrontera, Inc. Reports Q1 2025 Financial Results

TIPRANKS
·
17 May

Biofrontera Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Biofrontera Q1 Net Income USD -4.2 Million

THOMSON REUTERS
·
16 May

Biofrontera Q1 EPS $(0.47) Misses $(0.21) Estimate, Sales $8.59M Miss $10.55M Estimate

Benzinga
·
16 May

BRIEF-Biofrontera Announces New Patent Protection On Ameluz Until 2043

Reuters
·
16 May

Biofrontera's Revised Ameluz Formulation Receives US Patent Approval

MT Newswires Live
·
16 May

Biofrontera Inc. Announces New Patent Protection on Ameluz® Until 2043 and the Completion of Patient Enrollment in Phase 2B Study of Ameluz® (Aminolevulinic Acid Hci) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

THOMSON REUTERS
·
16 May